PUBLISHED DATE : Mar 2021 | Pages : 319
Fill out your details & get your free sample
Single-use Bioprocessing Market Size, Share, Trends Analysis Report by Products (Single-use Bioprocessing Equipment and Simple & Peripheral Devices); Application (Monoclonal Antibodies (mABs), Vaccines, Cell Therapies, Others)); End-users (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs), R&D Companies & Research Institutes); Method (Filtration, Storage & Transport, Cell Culture, Mixing, Purification); and Geography (North America, Europe, APAC, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026
319 Pages
117 Tables
157 Charts
5 Regions
21 Countries
47 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZE (REVENUE) | 12 BILLION (2026) |
| CAGR | 17% (2021–2026) |
| Base Year | 2020 |
| Forecast Year | 2021–2026 |
| Market Segments | Products (Single-use Bioprocessing Equipment and Simple & Peripheral Devices); Application (Monoclonal Antibodies (mABs), Vaccines, Cell Therapies, Others)); End-users (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs), R&D Companies & Research Institutes); Method (Filtration, Storage & Transport, Cell Culture, Mixing, Purification) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Switzerland, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Columbia, Saudi Arabia, Turkey, South Africa, and UAE |
The global single-use bioprocessing market size was valued at USD 4.8 billion in 2020 and is expected to reach USD 12 billion in 2026, growing at a CAGR of 17% during the forecast period. The outbreak of the COVID-19 pandemic has boosted the demand for single-use bioprocessing technology.
The ongoing robust R&D activities and clinical studies on the Covid-19 vaccine encourage many stakeholders to use SUB technology. Modalities such as covid-19 vaccine requirement, cell and gene therapies, and monoclonal antibodies are likely to influence the single-use bioprocessing market growth. The majority of biomanufacturing companies rely on advanced technology such as single-use systems to develop the vaccine.
Single-use technology is primarily used in pre-commercial development activities, production phases, and small biotech manufacturing. Single-use solutions have already supplanted a significant portion of traditional biopharmaceutical manufacturing practices, and this trend is expected to increase in the coming years. The biopharmaceutical industry's shift from traditional stainless-steel bioprocessing equipment to single-use ones is majorly influenced by proven economic and operational benefits of single-use bioprocessing technology. The market is likely to observe significant growth as single-use technology is increasing in downstream bioprocessing.
This research report includes a detailed segmentation by
Single-use bioprocessing products observe growth due to advances in equipment, higher scalability, and the increased application in the biopharmaceutical industry. Bioreactors and fermenters cover significant shares among SUB. The use of bioreactors and fermenters is growing for the development of biosimilars & biologics. The availability of single-use chromatography systems is considered a solution for single-use downstream bioprocessing. The use of membrane formats, scaling technologies, ion exchange technology, and polymeric column constructions are shifting end-users toward SUBs in downstream processes. Chromatography systems combined with tangential flow filtrations provide the highest productivity in downstream separation and purification steps.
Simple & peripheral elements accounted for over 45% single-use bioprocessing market share. The recurring use of tubing and filling, connectors, bags, sampling devices, probes and sensors, bottle assemblies, and manifolds is responsible for these devices' growth. Connectors, filling and tubing, and filters occupy a significant portion of the market share. Single-use connectors and tubing are prioritized for advanced aseptic processing, enabling reliability, flexibility, and cost-efficiency. Biopharmaceutical and pharmaceutical industries are currently relying on single-use solutions for the upstream process. However, with recent advances and increased SUB penetration, end-users are likely to use single-use technologies for commercial purposes. As this equipment is single-use in nature, the sales of simple and peripheral devices are rapidly increasing, thereby increasing their revenue shares.
The increased application of monoclonal antibodies (mABs) to diagnose and treat autoimmune disorders, cancer, and sexually transmitted infections (STIs) is boosting the single-use bioprocessing market growth. The production of mABs via single-use bioreactors reduces the operating cost and offers more flexibility than traditional stainless steel equipment. Also, the use of SUB in mABs manufacturing increases capacity, productivity, and flexibility. The utilization of SUBs in vaccine manufacturing is catching pace and is considered the smart method, especially during pandemics. They have become an ideal choice among manufacturers as they can be manufactured quickly and do not require validation, and have a reduced risk of contamination. Furthermore, single-use systems help enhance flexibility in small and large vaccine manufacturing and produce multiple products in a single suite.
Vaccine manufacturing via SUB has shifted to a large scale due to the increasing demand for high capacities. With the outbreak of the covid-19 pandemic, single-use technology has emerged as a critical factor for the rapid production of the COVID-19 vaccine in a short time. In addition to covid-19 vaccine production, single-use technology is finding application in the manufacturing of other vaccines such as influenza, thereby influencing the market growth.
Biopharmaceutical manufacturers occupy a significant share of the market, with single-use systems witnessing adoption in pre-commercial production processes. Several biopharmaceutical manufacturers have started to explore these solutions in commercial manufacturing. However, their potential benefits are significant, particularly for small-volume manufacturing in modular facilities. With the advent of single-use bioprocessing, the bioprocessing industry's dynamics have changed, enabling companies to develop new biologics with higher flexibility and low upfront costs. As technology has become increasingly popular, many companies are becoming interested in the widespread adoption of single-use bioprocessing.
In 2020, contract manufacturing organizations (CMO) accounted for over 34% share in the single-use bioprocessing market. Currently, over 10% of bioprocessing worldwide - about 1.7 million liters rely on single-use systems. It is expected that single-use covers 25–30% of the bioprocessing market in the future. CMOs use more SUB than biopharmaceutical developers as they offer quick switching over process lines and increased flexibility. Moreover, CMOs implementing SUB are likely to save on operating costs, capital investments, and floor space & process lines.
Advances in the cell culture process and biopharmaceutical manufacturing are leading to the development of innovative single-use technology. Single-use bioreactors are increasingly used for animal and human cell production processes. SUBs in mammalian cell culture result in high flexibility, reduced cost, and enhanced product productivity. They are increasingly being used for small-batch, large-batch volumes, clinical trials, and process development.
Filtration contributes to over 30% shares of the market. The application of disposable products is increasing from downstream sterilization and purification to upstream depth filtration and clarification. Single-use systems are used in membrane absorption and viral clearance. Single-use depth filters are applied to clarify cell culture streams in the first step of the downstream process. The increased demand for advanced filtration techniques is growing with growing challenges in the downstream bioprocessing and improvements in the biomass concentration during biologics manufacturing.
North America and Europe constitute over 75% of the market share; however, the APAC region is expected to grow at the fastest CAGR of over 19% during 2020-2026. The increasing spending on biopharmaceutical research activities in the US and Canada, large-scale manufacturing facilities, and the growing demand for single-use technology contribute to the region's growth.
Similarly, in Europe, the increasing adoption of disposable bioprocessing, increasing biopharmaceutical manufacturing, and growing chronic diseases across Europe are significant drivers influencing the market growth. However, the APAC region is poised for growth. It is likely to grow at the fastest CAGR during the forecast period because of the growth in the R&D infrastructure, increase in the awareness of disposables, expiry of blockbuster biologics, favorable government initiatives, and increased demand for biologics.
Thermo Fisher Scientific, Sartorius Stedim Biotech, Merck KGaA, Danaher Corporation, and Avantor are the key vendors operating in the global single-use bioprocessing market. The key players are increasing their focus on mergers and acquisitions in the past few years. With the sudden onset of the COVID-19 pandemic, vendors target vaccine developers and offer customized and flexible SUB technology. Acquisitions of emerging/small, specialized single-use suppliers, product portfolio development, expansion in regional markets, and strengthening of global distribution networks are the major strategies adopted by vendors in the market.
Product
Application
End-users
Method
Geography
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
Fill out your details & get your free sample
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
Want to know more about the report or any specific requirement?
Click to Email +1-312-235-2040
